In this infographic, we explore the current landscape of ligand binding assays (LBAs) and critical reagents through comprehensive survey questions.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
In this poster, we validate ultra-high sensitive SIMOA assays for the successful quantitation of neurofilament light chain (NF-L) and glial fibrillary acidic protein (GFAP).
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
Alzheimer's disease is a devastating neurodegenerative disease, which is the only one among the top 10 deadly diseases that have almost no treatment. FDA-approved ADUHELM® from Biogen in 2021 was the first approved Alzheimer's treatment in the past 2 decades.
Current treatment plans focus on two strategies, preventing the formation and aggregation of plague proteins called amyloids and taus, or removing such proteins. ADUHELM® adopted the later pathway. Meanwhile, from the diagnostic point-of-view, we are slightly ahead of time compared with the treatment, thanks to various new technologies. In particular, highly sensitive technology and platforms enable early diagnostics.
It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.